Last reviewed · How we verify
Hydatidiform mole, benign — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Prepidil | DINOPROSTONE | Pfizer | Prostaglandin Analog [EPC] | Prostaglandin E2 receptor EP4 subtype | 1977-01-01 | |
| Enzaprost | DINOPROST | Pfizer | dinoprost | Prostaglandin F2-alpha receptor | 1976-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Hydatidiform mole, benign
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hydatidiform mole, benign:
- Hydatidiform mole, benign treatment updates — RSS
- Hydatidiform mole, benign treatment updates — Atom
- Hydatidiform mole, benign treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hydatidiform mole, benign — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hydatidiform-mole-benign. Accessed 2026-06-10.
Related
- Hydatidiform mole, benign full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing